Eden Research plc - New authorisations for Cedroz and Mevalone
("Eden" or "Company")
New authorisations for Cedroz™ and Mevalone™
Eden-developed Cedroz is a bionematicide that tackles root knot nematodes, a pest that causes severe damage to crops globally, both in open field and greenhouse situations.
After a successful summer harvest in 2019 applying Cedroz to crops in
The demand for Cedroz stems from it being residue-free and having a zero-day pre-harvest interval, which allows for applications right up to harvest. This stands Eden's product in good stead for inclusion in crop protection programmes that meet consumer demand for quality produce that is free from pesticide residues and intentionally added plastics. Heightened consumer awareness about the origins and standards of the food they purchase and the presence of microplastics in the environment are clear drivers for increasing regulatory scrutiny of crop protection products in today's market and in future years. Both active ingredients used in Cedroz, geraniol and thymol, also received approval as organic inputs across the EU earlier this year.
We are pleased to also announce that the Greek authorities have now authorised the use of Mevlone on both olives and tomatoes for the treatment of several minor diseases affecting these crops. As a part of its registration strategy, Eden's partner K&N Efthymiadis has sought authorisation to sell Eden's fungicide, Mevalone, for use on an expanding range of crops. This serves to further expand the addressable market for Mevalone in
The importance of, and growing demand for, biopesticide products in
We are also pleased with the ongoing sales development of Mevalone in
The information contained herein is not expected to have a significant impact on management's expectations of performance for the year.
For further information contact:
| || |
01285 359 555
Cenkos Securities plc (Nominated advisor and broker)
| || |
020 7397 8900
| || |
Eden's Sustaine encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. They produce stabilised aqueous suspensions which, are easy to mix and apply, have phased release patterns, are safer for the environment and the crops themselves.
By 2025 in the EU, pesticides containing synthetic polymer microplastics are likely to be banned and removed from the market. The only acceptable alternative is the substitution with biodegradable formulations. Reformulated products will need to be evaluated and registered within the five-year transition period.
Sustaine is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Sustaine provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of 14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.
Mevalone is a foliar fungicide which has been authorised for sale in
Cedroz is a nematicide which has been authorised for sale in
Eden was admitted to trading on AIM on
This information is provided by RNS, the news service of the
Quick facts: Eden Research PLC
Market Cap: £28.43 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE